title stringlengths 3 1.99k | abstract stringlengths 1 512 | pmid stringlengths 6 8 | abstract embedding list | title embedding list |
|---|---|---|---|---|
Mechanical strength of the titin Z1Z2-telethonin complex. | Using molecular dynamics simulations; we have explored the mechanical strength of the titin Z1Z2-telethonin complex; namely; its ability to bear strong forces such as those encountered during passive muscle stretch. Our results show that not only does this complex resist considerable mechanical force through beta stran... | 16531234 | [
-0.104372345,
-0.0048231278,
-0.0066520204,
0.009831125,
0.00823332,
0.028998189,
0.03208816,
0.032140978,
-0.03842656,
-0.015066909,
-0.0058993353,
-0.012822058,
0.017245734,
0.024851818,
0.03795118,
-0.03771349,
-0.0036379786,
0.03319738,
-0.07484596,
0.03599684,
0.01445947... | [
-0.104372345,
-0.0048231278,
-0.0066520204,
0.009831125,
0.00823332,
0.028998189,
0.03208816,
0.032140978,
-0.03842656,
-0.015066909,
-0.0058993353,
-0.012822058,
0.017245734,
0.024851818,
0.03795118,
-0.03771349,
-0.0036379786,
0.03319738,
-0.07484596,
0.03599684,
0.01445947... |
Mechanical strength of the titin Z1Z2-telethonin complex. | o protect the proximal Z1 domains from bearing too much stress. Our simulations also reveal that without telethonin; apo-titin Z1Z2 exhibits significantly decreased resistance to mechanical stress; and that the N-terminal segment of telethonin (residues 1-89) does not exhibit a stable fold conformation when it is unbou... | 16531234 | [
-0.0933708,
0.0053855134,
0.008247491,
0.015075495,
-0.026917709,
0.019228812,
0.031281322,
0.025366787,
-0.03874678,
-0.029441245,
-0.019452251,
-0.008930949,
0.02965154,
0.027101716,
0.032516804,
-0.017493881,
-0.020714018,
0.04910379,
-0.06009168,
0.04594937,
0.04960324,
... | [
-0.0933708,
0.0053855134,
0.008247491,
0.015075495,
-0.026917709,
0.019228812,
0.031281322,
0.025366787,
-0.03874678,
-0.029441245,
-0.019452251,
-0.008930949,
0.02965154,
0.027101716,
0.032516804,
-0.017493881,
-0.020714018,
0.04910379,
-0.06009168,
0.04594937,
0.04960324,
... |
Mechanical strength of the titin Z1Z2-telethonin complex. | ns together. | 16531234 | [
0.00946925,
0.02402469,
-0.038244992,
-0.027914902,
-0.0013931167,
0.005470611,
0.07028668,
-0.05243901,
0.057985194,
-0.029886294,
-0.023301847,
-0.041399222,
0.08406013,
0.03750901,
0.06303196,
-0.0028388037,
-0.030779991,
-0.0118677765,
-0.025496662,
0.083744705,
-0.031463... | [
0.00946925,
0.02402469,
-0.038244992,
-0.027914902,
-0.0013931167,
0.005470611,
0.07028668,
-0.05243901,
0.057985194,
-0.029886294,
-0.023301847,
-0.041399222,
0.08406013,
0.03750901,
0.06303196,
-0.0028388037,
-0.030779991,
-0.0118677765,
-0.025496662,
0.083744705,
-0.031463... |
Structural basis of RNA binding discrimination between bacteriophages Qbeta and MS2. | Sequence-specific interactions between RNA stem-loops and coat protein (CP) subunits play vital roles in the life cycles of the RNA bacteriophages; e.g.; by allowing translational repression of their replicase cistrons and tagging their own RNA genomes for encapsidation. The CPs of bacteriophages Qbeta and MS2 each dis... | 16531233 | [
-0.11112356,
0.021747936,
-0.07330107,
-0.007424663,
0.020083213,
-0.030231362,
0.034386512,
-0.00033918725,
0.016114514,
0.02623603,
0.0039054393,
-0.027860798,
0.038088854,
0.011533198,
0.007710995,
-0.010014972,
-0.11538526,
0.007677701,
-0.008363566,
-0.020269662,
-0.0102... | [
-0.11112356,
0.021747936,
-0.07330107,
-0.007424663,
0.020083213,
-0.030231362,
0.034386512,
-0.00033918725,
0.016114514,
0.02623603,
0.0039054393,
-0.027860798,
0.038088854,
0.011533198,
0.007710995,
-0.010014972,
-0.11538526,
0.007677701,
-0.008363566,
-0.020269662,
-0.0102... |
Structural basis of RNA binding discrimination between bacteriophages Qbeta and MS2. | o relax this discrimination in vitro. We have determined the structures of eight complexes between such mutants and both MS2 and Qbeta stem-loops with X-ray crystallography. In conjunction with previously determined in vivo repression data; the structures enable us to propose the molecular basis for the discrimination ... | 16531233 | [
-0.0723426,
-0.014439349,
-0.06751622,
0.047945537,
0.04786598,
0.013192978,
0.010952161,
0.015791796,
0.0197298,
0.034659743,
-0.006119155,
-0.018682318,
-0.008790899,
0.022567285,
0.007650601,
-0.0024612527,
-0.078707054,
0.010567642,
-0.041766714,
-0.0035534855,
-0.0099444... | [
-0.0723426,
-0.014439349,
-0.06751622,
0.047945537,
0.04786598,
0.013192978,
0.010952161,
0.015791796,
0.0197298,
0.034659743,
-0.006119155,
-0.018682318,
-0.008790899,
0.022567285,
0.007650601,
-0.0024612527,
-0.078707054,
0.010567642,
-0.041766714,
-0.0035534855,
-0.0099444... |
Cryo-electron microscopy studies of human TFIID: conformational breathing in the integration of gene regulatory cues. | The multisubunit transcription factor TFIID is essential for directing eukaryotic promoter recognition and mediating interactions with activators/cofactors during assembly of the preinitiation complex. Despite its central role in transcription initiation and regulation; structural knowledge of the TFIID complex has so ... | 16531235 | [
-0.033204343,
-0.035786904,
0.0018644503,
0.019356025,
0.042111542,
0.008077089,
0.014731134,
0.032888114,
-0.024890082,
-0.048989583,
-0.018855324,
-0.061507095,
0.01940873,
0.008801786,
0.0073985076,
0.005194767,
-0.07615917,
0.015113248,
-0.059451587,
-0.022162583,
0.07357... | [
-0.033204343,
-0.035786904,
0.0018644503,
0.019356025,
0.042111542,
0.008077089,
0.014731134,
0.032888114,
-0.024890082,
-0.048989583,
-0.018855324,
-0.061507095,
0.01940873,
0.008801786,
0.0073985076,
0.005194767,
-0.07615917,
0.015113248,
-0.059451587,
-0.022162583,
0.07357... |
Cryo-electron microscopy studies of human TFIID: conformational breathing in the integration of gene regulatory cues. | . The improved cryopreservation has allowed for a more detailed definition of the structural elements in the complex and for the detection; by an extensive statistical analysis of the data; of a conformational opening and closing of the cavity central to the TFIID architecture. We propose that these density rearrangeme... | 16531235 | [
-0.049897816,
-0.037979547,
0.005836641,
0.03337115,
0.025107818,
-0.03551644,
0.038059004,
0.02526673,
-0.012785654,
-0.06562993,
0.008230226,
-0.05249335,
0.03835034,
0.023624657,
0.046481244,
0.03241769,
-0.044998083,
0.015533476,
-0.047461193,
0.0049195965,
0.03625802,
... | [
-0.049897816,
-0.037979547,
0.005836641,
0.03337115,
0.025107818,
-0.03551644,
0.038059004,
0.02526673,
-0.012785654,
-0.06562993,
0.008230226,
-0.05249335,
0.03835034,
0.023624657,
0.046481244,
0.03241769,
-0.044998083,
0.015533476,
-0.047461193,
0.0049195965,
0.03625802,
... |
Unfolding barriers in bacteriorhodopsin probed from the cytoplasmic and the extracellular side by AFM. | Selecting an individual membrane protein and probing its mechanical properties has become possible by AFM-based single-molecule force spectroscopy. In contrast to earlier studies; we extracted and unfolded bacteriorhodopsin monomers from the purple membrane not only from the cytoplasmic side; but also from the extracel... | 16531236 | [
-0.15641287,
-0.043292847,
-0.03283195,
0.013912735,
-0.051724806,
0.006462307,
0.054333445,
0.012226343,
0.0006480423,
0.031672552,
0.0077732136,
-0.059287224,
-0.05549284,
0.022898043,
0.06329241,
-0.048457425,
-0.005793679,
0.061237115,
-0.05370105,
-0.0160339,
0.010684875... | [
-0.15641287,
-0.043292847,
-0.03283195,
0.013912735,
-0.051724806,
0.006462307,
0.054333445,
0.012226343,
0.0006480423,
0.031672552,
0.0077732136,
-0.059287224,
-0.05549284,
0.022898043,
0.06329241,
-0.048457425,
-0.005793679,
0.061237115,
-0.05370105,
-0.0160339,
0.010684875... |
Unfolding barriers in bacteriorhodopsin probed from the cytoplasmic and the extracellular side by AFM. | ative to the amino acid sequences is given at an accuracy of +/-3 aa. Most barriers were found to provide resistance to forced unfolding only when extracted toward one of the sides. However; certain barriers have identical positions to within a few amino acids when probed from either of the sides; which typifies them a... | 16531236 | [
-0.077223144,
-0.021278737,
-0.014234376,
0.06673605,
-0.033473954,
0.014154928,
0.038293783,
-0.034612704,
0.00034054916,
0.0019514336,
0.052859187,
-0.044623114,
0.0050780308,
-0.0015765398,
0.050263897,
0.020378329,
-0.10582431,
0.024125611,
0.0101560615,
0.022417486,
-0.0... | [
-0.077223144,
-0.021278737,
-0.014234376,
0.06673605,
-0.033473954,
0.014154928,
0.038293783,
-0.034612704,
0.00034054916,
0.0019514336,
0.052859187,
-0.044623114,
0.0050780308,
-0.0015765398,
0.050263897,
0.020378329,
-0.10582431,
0.024125611,
0.0101560615,
0.022417486,
-0.0... |
Conformational and sequence signatures in beta helix proteins. | beta helix proteins are characterized by a repetitive fold; in which the repeating unit is a beta-helical coil formed by three strand segments linked by three loop segments. Using a data set of left- and right-handed beta helix proteins; we have examined conformational features at equivalent positions in successive coi... | 16531237 | [
-0.08382523,
-0.0482998,
0.028293654,
-0.016772963,
-0.019742213,
0.030431515,
0.015901985,
-0.02007213,
-0.008934144,
-0.0058395253,
-0.032094296,
-0.084194735,
-0.00016207156,
0.018778857,
-0.02517924,
-0.018778857,
-0.054950923,
0.027976934,
-0.020599997,
0.018132221,
0.05... | [
-0.08382523,
-0.0482998,
0.028293654,
-0.016772963,
-0.019742213,
0.030431515,
0.015901985,
-0.02007213,
-0.008934144,
-0.0058395253,
-0.032094296,
-0.084194735,
-0.00016207156,
0.018778857,
-0.02517924,
-0.018778857,
-0.054950923,
0.027976934,
-0.020599997,
0.018132221,
0.05... |
Conformational and sequence signatures in beta helix proteins. | corners" with the conformational sequence P(II)-P(II)-alpha(L)-P(II); which imposes sequence restrictions; resulting in the first and third P(II) residues often being G and a small; uncharged residue (V; A; S; T; C); respectively. Right-handed beta helices feature mid-sized loops (4; 5; or 6 residues) of conserved conf... | 16531237 | [
-0.07114714,
-0.025894495,
-0.030714225,
-0.009969578,
-0.025920905,
0.067185715,
0.014023433,
0.016347468,
0.0031872941,
0.010999548,
0.019701472,
-0.04360205,
-0.018011265,
-0.012531298,
-0.056040917,
-0.0033936182,
-0.07320708,
0.032589298,
-0.024930548,
0.031374462,
0.056... | [
-0.07114714,
-0.025894495,
-0.030714225,
-0.009969578,
-0.025920905,
0.067185715,
0.014023433,
0.016347468,
0.0031872941,
0.010999548,
0.019701472,
-0.04360205,
-0.018011265,
-0.012531298,
-0.056040917,
-0.0033936182,
-0.07320708,
0.032589298,
-0.024930548,
0.031374462,
0.056... |
Conformational and sequence signatures in beta helix proteins. | continuous; loopless beta helices (Perutz nanotubes) have also been investigated. | 16531237 | [
-0.041135985,
0.011498956,
-0.0052946983,
0.010688983,
-0.0025560611,
0.05688398,
-0.03818822,
0.041428108,
-0.04134844,
0.0005410883,
-0.019890804,
-0.015429314,
0.039648823,
0.090185806,
0.033753287,
0.024843587,
0.028999675,
-0.0014365396,
-0.04233103,
0.060017645,
0.03882... | [
-0.041135985,
0.011498956,
-0.0052946983,
0.010688983,
-0.0025560611,
0.05688398,
-0.03818822,
0.041428108,
-0.04134844,
0.0005410883,
-0.019890804,
-0.015429314,
0.039648823,
0.090185806,
0.033753287,
0.024843587,
0.028999675,
-0.0014365396,
-0.04233103,
0.060017645,
0.03882... |
Structural determinants for high-affinity binding in a Nedd4 WW3* domain-Comm PY motif complex. | Interactions between the WW domains of Drosophila Nedd4 (dNedd4) and Commissureless (Comm) PY motifs promote axon crossing at the CNS midline and muscle synaptogenesis. Here we report the solution structure of the dNedd4 WW3* domain complexed to the second PY motif (227'TGLPSYDEALH237') of Comm. Unexpectedly; there are... | 16531238 | [
-0.043132983,
-0.040415738,
-0.0055268253,
-0.01664643,
-0.03411067,
0.022885542,
0.00076463766,
-0.0050684554,
-0.0064666495,
-0.038067825,
0.019944059,
-0.061784368,
0.012511203,
0.028702559,
-0.01333561,
0.020722298,
-0.1369703,
0.058091026,
-0.029968848,
0.006641424,
0.05... | [
-0.043132983,
-0.040415738,
-0.0055268253,
-0.01664643,
-0.03411067,
0.022885542,
0.00076463766,
-0.0050684554,
-0.0064666495,
-0.038067825,
0.019944059,
-0.061784368,
0.012511203,
0.028702559,
-0.01333561,
0.020722298,
-0.1369703,
0.058091026,
-0.029968848,
0.006641424,
0.05... |
Structural determinants for high-affinity binding in a Nedd4 WW3* domain-Comm PY motif complex. | udies confirm the importance of these extensive contacts; not simultaneously observed in other WW domain complexes; and identify a variable loop in WW3* responsible for its high-affinity interaction. These studies expand our general understanding of the molecular determinants involved in WW domain-ligand recognition. I... | 16531238 | [
-0.042599484,
-0.031195523,
-0.02215967,
0.0002277981,
0.008096548,
-0.0043095597,
0.033285808,
0.022993138,
-0.02751768,
-0.043313887,
-0.0039159777,
-0.054453254,
0.019341754,
0.044451635,
-0.022239048,
0.027729355,
-0.07096386,
0.028840644,
-0.044160582,
0.040694416,
-0.00... | [
-0.042599484,
-0.031195523,
-0.02215967,
0.0002277981,
0.008096548,
-0.0043095597,
0.033285808,
0.022993138,
-0.02751768,
-0.043313887,
-0.0039159777,
-0.054453254,
0.019341754,
0.044451635,
-0.022239048,
0.027729355,
-0.07096386,
0.028840644,
-0.044160582,
0.040694416,
-0.00... |
Structural determinants for high-affinity binding in a Nedd4 WW3* domain-Comm PY motif complex. | and muscle development. | 16531238 | [
-0.03630271,
-0.060486954,
0.06991828,
-0.0013361598,
-0.033220407,
0.012954905,
-0.0059011662,
0.0034181979,
0.0142391985,
-0.0014662356,
0.016570685,
-0.026133737,
-0.0034577146,
0.029295076,
0.023565149,
-0.0014489471,
-0.003340811,
0.009958218,
-0.10311235,
0.010577314,
-... | [
-0.03630271,
-0.060486954,
0.06991828,
-0.0013361598,
-0.033220407,
0.012954905,
-0.0059011662,
0.0034181979,
0.0142391985,
-0.0014662356,
0.016570685,
-0.026133737,
-0.0034577146,
0.029295076,
0.023565149,
-0.0014489471,
-0.003340811,
0.009958218,
-0.10311235,
0.010577314,
-... |
Principles of protein-DNA recognition revealed in the structural analysis of Ndt80-MSE DNA complexes. | The Saccharomyces cerevisiae transcription factor Ndt80 selectively binds a DNA consensus sequence (the middle sporulation element [MSE]) to activate gene expression after the successful completion of meiotic recombination. Here we report the X-ray crystal structures of Ndt80 bound to ten distinct MSE variants. Compari... | 16531239 | [
-0.057981808,
0.008947238,
-0.02236479,
-0.03539218,
0.06655211,
0.058986966,
-0.010183848,
0.04933215,
-0.02067189,
0.0155535145,
-0.0011746143,
-0.049623117,
0.001428384,
-0.0062326477,
-0.033223152,
-0.0030766465,
-0.107499115,
0.03163606,
-0.011599007,
0.003458541,
0.0762... | [
-0.057981808,
0.008947238,
-0.02236479,
-0.03539218,
0.06655211,
0.058986966,
-0.010183848,
0.04933215,
-0.02067189,
0.0155535145,
-0.0011746143,
-0.049623117,
0.001428384,
-0.0062326477,
-0.033223152,
-0.0030766465,
-0.107499115,
0.03163606,
-0.011599007,
0.003458541,
0.0762... |
Principles of protein-DNA recognition revealed in the structural analysis of Ndt80-MSE DNA complexes. | ch end of the MSE contains distinct 5'-YpG-3' steps that are recognized by arginine side chains through a combination of hydrogen bonding and cation-pi interactions. The 3' AT-rich region is recognized via minor groove contacts that sterically exclude the N2 atom of GC base pairs. The conformation of the AT-rich region... | 16531239 | [
-0.12377076,
0.0013730159,
-0.009125984,
0.0019306234,
0.004665124,
0.02067678,
0.03170703,
0.0075972998,
-0.015616306,
-0.00418741,
0.01511553,
-0.07743579,
-0.0017873093,
-0.020241896,
0.01581398,
-0.027226403,
-0.056508623,
0.038876034,
-0.033894632,
-0.005146133,
-0.02206... | [
-0.12377076,
0.0013730159,
-0.009125984,
0.0019306234,
0.004665124,
0.02067678,
0.03170703,
0.0075972998,
-0.015616306,
-0.00418741,
0.01511553,
-0.07743579,
-0.0017873093,
-0.020241896,
0.01581398,
-0.027226403,
-0.056508623,
0.038876034,
-0.033894632,
-0.005146133,
-0.02206... |
Structure-guided engineering of xylitol dehydrogenase cosubstrate specificity. | Xylitol dehydrogenase (XDH) is one of several enzymes responsible for assimilating xylose into eukaryotic metabolism and is useful for fermentation of xylose contained in agricultural byproducts to produce ethanol. For efficient xylose utilization at high flux rates; cosubstrates should be recycled between the NAD+-spe... | 16531240 | [
-0.03496878,
0.017404612,
-0.008522809,
0.04552589,
0.03451671,
-0.07536237,
-0.03890443,
-0.0005031748,
-0.052253723,
-0.009520017,
0.012591419,
-0.06679967,
-0.01019147,
-0.021233892,
-0.019930873,
-0.021300374,
-0.033851903,
0.06281084,
-0.07738338,
-0.028214352,
0.0621726... | [
-0.03496878,
0.017404612,
-0.008522809,
0.04552589,
0.03451671,
-0.07536237,
-0.03890443,
-0.0005031748,
-0.052253723,
-0.009520017,
0.012591419,
-0.06679967,
-0.01019147,
-0.021233892,
-0.019930873,
-0.021300374,
-0.033851903,
0.06281084,
-0.07738338,
-0.028214352,
0.0621726... |
Structure-guided engineering of xylitol dehydrogenase cosubstrate specificity. | nobacter oxydans holoenzyme to 1.9 angstroms resolution. The structure reveals that NAD+ specificity is largely conferred by Asp38; which interacts with the hydroxyls of the adenosine ribose. Met39 stacked under the purine ring and was also located near the 2' hydroxyl. Based on the location of these residues and on se... | 16531240 | [
-0.08949047,
0.026088072,
-0.10792125,
-0.008975682,
0.04900669,
-0.027779335,
0.026194608,
-0.020814527,
-0.04639655,
-0.011465968,
0.045597527,
-0.06514694,
-0.008656072,
-0.000330637,
-0.030149767,
-0.032893077,
-0.028471822,
0.023464616,
-0.0469825,
0.00642214,
0.00150232... | [
-0.08949047,
0.026088072,
-0.10792125,
-0.008975682,
0.04900669,
-0.027779335,
0.026194608,
-0.020814527,
-0.04639655,
-0.011465968,
0.045597527,
-0.06514694,
-0.008656072,
-0.000330637,
-0.030149767,
-0.032893077,
-0.028471822,
0.023464616,
-0.0469825,
0.00642214,
0.00150232... |
Conformational flexibility in the multidrug efflux system protein AcrA. | Intrinsic resistance to multiple drugs in many gram-negative bacterial pathogens is conferred by resistance nodulation cell division efflux pumps; which are composed of three essential components as typified by the extensively characterized Escherichia coli AcrA-AcrB-TolC system. The inner membrane drug:proton antiport... | 16531241 | [
-0.050115857,
-0.07094634,
-0.06342497,
0.02189735,
0.03867376,
-0.014629349,
0.0650786,
0.016443016,
-0.025057929,
-0.020017004,
-0.03083232,
-0.08774943,
0.0192702,
-0.04264782,
0.017429862,
0.00625448,
-0.04072747,
0.022417445,
-0.0071479776,
0.01010852,
0.006331161,
-0.... | [
-0.050115857,
-0.07094634,
-0.06342497,
0.02189735,
0.03867376,
-0.014629349,
0.0650786,
0.016443016,
-0.025057929,
-0.020017004,
-0.03083232,
-0.08774943,
0.0192702,
-0.04264782,
0.017429862,
0.00625448,
-0.04072747,
0.022417445,
-0.0071479776,
0.01010852,
0.006331161,
-0.... |
Conformational flexibility in the multidrug efflux system protein AcrA. | ystal structures of AcrB and TolC have previously been determined; and we complete the molecular picture of the efflux system by presenting the structure of a stable fragment of AcrA. The AcrA fragment resembles the elongated sickle shape of its homolog Pseudomonas aeruginosa MexA; being composed of three domains: beta... | 16531241 | [
-0.08121602,
-0.06581937,
-0.047301058,
0.022354247,
0.03193086,
-0.004503918,
0.0033630577,
-0.018081808,
-0.04518468,
-0.024430944,
-0.004622964,
-0.08735352,
-0.0063292943,
-0.0026372059,
0.019695546,
-0.021732561,
-0.03931173,
0.043147665,
-0.021468014,
0.04222175,
0.0405... | [
-0.08121602,
-0.06581937,
-0.047301058,
0.022354247,
0.03193086,
-0.004503918,
0.0033630577,
-0.018081808,
-0.04518468,
-0.024430944,
-0.004622964,
-0.08735352,
-0.0063292943,
-0.0026372059,
0.019695546,
-0.021732561,
-0.03931173,
0.043147665,
-0.021468014,
0.04222175,
0.0405... |
Conformational flexibility in the multidrug efflux system protein AcrA. | e in coupling between AcrA conformations and TolC channel opening. | 16531241 | [
-0.073389664,
-0.0552668,
-0.0552668,
0.030618655,
-0.050617203,
0.0076084314,
0.03307554,
0.030011036,
0.025229348,
-0.053074095,
-0.016141498,
-0.06583407,
-0.02805609,
0.031305525,
0.07967719,
-0.026048312,
-0.03526825,
0.003830634,
-0.056376364,
0.061607163,
0.02275925,
... | [
-0.073389664,
-0.0552668,
-0.0552668,
0.030618655,
-0.050617203,
0.0076084314,
0.03307554,
0.030011036,
0.025229348,
-0.053074095,
-0.016141498,
-0.06583407,
-0.02805609,
0.031305525,
0.07967719,
-0.026048312,
-0.03526825,
0.003830634,
-0.056376364,
0.061607163,
0.02275925,
... |
Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. | Rho-kinase is a key regulator of cytoskeletal events and a promising drug target in the treatment of vascular diseases and neurological disorders. Unlike other protein kinases; Rho-kinase requires both N- and C-terminal extension segments outside the kinase domain for activity; although the details of this requirement ... | 16531242 | [
-0.035432268,
-0.029641986,
0.0050233337,
-0.0021862958,
-0.037371214,
-0.02831394,
0.045525417,
0.0006316519,
-0.0004131468,
-0.011905932,
0.011016142,
-0.005869963,
0.017835658,
0.055193592,
0.016547453,
-0.030518496,
-0.047517486,
0.07160824,
-0.028977964,
-0.017755974,
0.... | [
-0.035432268,
-0.029641986,
0.0050233337,
-0.0021862958,
-0.037371214,
-0.02831394,
0.045525417,
0.0006316519,
-0.0004131468,
-0.011905932,
0.011016142,
-0.005869963,
0.017835658,
0.055193592,
0.016547453,
-0.030518496,
-0.047517486,
0.07160824,
-0.028977964,
-0.017755974,
0.... |
Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. | n forming a helix bundle that structurally integrates the C-terminal extension. This structural organization enables binding of the C-terminal hydrophobic motif to the N-terminal lobe; which defines the correct disposition of helix alphaC that is important for the catalytic activity. The bound inhibitor fasudil signifi... | 16531242 | [
-0.03723705,
-0.06639286,
0.013521538,
0.025234042,
-0.02934068,
0.024851108,
0.06095256,
0.024745472,
-0.030634735,
-0.027650489,
0.028627632,
-0.03760678,
0.004905519,
0.025379293,
-0.004760268,
-0.004776774,
-0.043733723,
0.06301248,
-0.04890994,
-0.034279212,
-0.02799381,... | [
-0.03723705,
-0.06639286,
0.013521538,
0.025234042,
-0.02934068,
0.024851108,
0.06095256,
0.024745472,
-0.030634735,
-0.027650489,
0.028627632,
-0.03760678,
0.004905519,
0.025379293,
-0.004760268,
-0.004776774,
-0.043733723,
0.06301248,
-0.04890994,
-0.034279212,
-0.02799381,... |
Molecular mechanism for the regulation of rho-kinase by dimerization and its inhibition by fasudil. | and stability confer selectivity. | 16531242 | [
-0.061009996,
-0.020963961,
-0.020134877,
-0.04369137,
-0.06174696,
0.013311392,
0.040559277,
0.03158412,
0.017397588,
-0.022569487,
-0.030189157,
0.048297387,
0.032084204,
0.0009952289,
0.028952112,
0.094225965,
0.0076262495,
0.014133895,
0.0025645648,
0.05500901,
-0.0803289... | [
-0.061009996,
-0.020963961,
-0.020134877,
-0.04369137,
-0.06174696,
0.013311392,
0.040559277,
0.03158412,
0.017397588,
-0.022569487,
-0.030189157,
0.048297387,
0.032084204,
0.0009952289,
0.028952112,
0.094225965,
0.0076262495,
0.014133895,
0.0025645648,
0.05500901,
-0.0803289... |
Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein. | We report the serendipitous discovery of a human plasma phosphate binding protein (HPBP). This 38 kDa protein is copurified with the enzyme paraoxonase. Its X-ray structure is similar to the prokaryotic phosphate solute binding proteins (SBPs) associated with ATP binding cassette transmembrane transporters; though phos... | 16531243 | [
-0.10847691,
0.023405531,
0.0016131777,
-0.030581819,
0.049533557,
-0.033938684,
0.077445745,
0.042026874,
-0.0017758997,
0.01535699,
-0.00034712645,
-0.09367499,
-0.00067649386,
0.035286713,
-0.006498967,
-0.018092701,
-0.006069447,
0.009469262,
-0.041762553,
0.035947513,
0.... | [
-0.10847691,
0.023405531,
0.0016131777,
-0.030581819,
0.049533557,
-0.033938684,
0.077445745,
0.042026874,
-0.0017758997,
0.01535699,
-0.00034712645,
-0.09367499,
-0.00067649386,
0.035286713,
-0.006498967,
-0.018092701,
-0.006069447,
0.009469262,
-0.041762553,
0.035947513,
0.... |
Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein. | phosphate-SBPs are also widespread in eukaryotes. The systematic absence of complete genes for eukaryotic phosphate-SBP from databases is intriguing; but the astonishing 90% sequence conservation between genes belonging to evolutionary distant species suggests that the corresponding proteins play an important function.... | 16531243 | [
-0.06832378,
0.011305135,
0.0032926123,
-0.071308285,
0.027926413,
-0.07109511,
0.07168135,
0.05382763,
-0.013303685,
0.025141766,
0.002674727,
-0.064379975,
-0.024688762,
0.034828074,
-0.029551903,
-0.006441995,
-0.023596222,
0.0026164358,
-0.038025755,
-0.009199995,
0.07205... | [
-0.06832378,
0.011305135,
0.0032926123,
-0.071308285,
0.027926413,
-0.07109511,
0.07168135,
0.05382763,
-0.013303685,
0.025141766,
0.002674727,
-0.064379975,
-0.024688762,
0.034828074,
-0.029551903,
-0.006441995,
-0.023596222,
0.0026164358,
-0.038025755,
-0.009199995,
0.07205... |
Serendipitous discovery and X-ray structure of a human phosphate binding apolipoprotein. | atherosclerosis. | 16531243 | [
-0.01967671,
0.0017549676,
0.0060222056,
0.0502059,
0.016963588,
0.014922163,
0.044068452,
0.061374474,
0.054525822,
-0.012637083,
0.0097329905,
-0.08766277,
0.0070330407,
-0.030107737,
-0.043515295,
-0.017042613,
-0.019887438,
0.00032638115,
-0.022429341,
0.063007616,
0.0141... | [
-0.01967671,
0.0017549676,
0.0060222056,
0.0502059,
0.016963588,
0.014922163,
0.044068452,
0.061374474,
0.054525822,
-0.012637083,
0.0097329905,
-0.08766277,
0.0070330407,
-0.030107737,
-0.043515295,
-0.017042613,
-0.019887438,
0.00032638115,
-0.022429341,
0.063007616,
0.0141... |
Patchwork HBA1 and HBA2 genes. | nan | 16531244 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
Iron regulatory protein 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiency. | nan | 16531245 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
CD34 and CD2 expression in acute promyelocytic leukemia. | nan | 16531246 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
Novel homeobox gene recombination in T-cell acute lymphoblastic leukemia. | nan | 16531247 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation. | nan | 16531248 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
The role of graft-versus-host disease in the inhibition of normal B-lymphopoiesis and leukemic control of B-lineage acute lymphocytic leukemia after allogeneic stem cell transplantation. | nan | 16531250 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
Biclonality versus intraclonal evolution of a single tumor cell clone in B-cell chronic lymphoproliferative disorders. | nan | 16531249 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. | nan | 16531251 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
Registration of clinical trials: a step forward but still a long path ahead. | nan | 16531252 | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... | [
-0.034312993,
-0.0094465185,
0.028019665,
-0.06575351,
0.03799498,
0.040945794,
0.07881021,
0.0050300914,
0.046821304,
0.008036396,
-0.0047722217,
-0.098238565,
0.043139316,
0.027993552,
0.022953669,
0.020525124,
-0.05415917,
-0.022000529,
-0.068782665,
0.0146104405,
0.066641... |
The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. | Acute promyelocytic leukemia (APL) is characterized by leukemic cells blocked at the promyelocytic stage of granulocytic differentiation. To date; it is still not clear whether CD34 expression identifies a subset of APL patients with peculiar characteristics. We; therefore; conducted a detailed analysis of CD34 express... | 16531253 | [
-0.098114975,
0.019769633,
-0.03290051,
-0.020782778,
-0.025035314,
-0.0072119837,
0.04148557,
0.03724636,
0.022062538,
-0.036286544,
0.03479349,
-0.033167128,
-0.0143706435,
-0.03546003,
-0.044418354,
0.018009963,
0.04260536,
-0.0043558516,
-0.055083025,
-0.0006311319,
-0.00... | [
-0.098114975,
0.019769633,
-0.03290051,
-0.020782778,
-0.025035314,
-0.0072119837,
0.04148557,
0.03724636,
0.022062538,
-0.036286544,
0.03479349,
-0.033167128,
-0.0143706435,
-0.03546003,
-0.044418354,
0.018009963,
0.04260536,
-0.0043558516,
-0.055083025,
-0.0006311319,
-0.00... |
The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. | ) cases were classified as hypergranular (M3) and 12 (9%) as the hyporgranular M3 variant (M3v). The parameters considered were white blood cell (WBC) and platelet counts; hemoglobin levels; percentage of peripheral blood leukemic promyelocytes (PBLP); CD15; CD56 and HLA-DR expression; and the PML/RARalpha isoform; to ... | 16531253 | [
-0.06588581,
-0.0069880905,
-0.04892327,
0.0001806335,
-0.0031904315,
-0.013869999,
0.041490544,
0.041835632,
-0.0074791815,
-0.014029272,
0.01538309,
-0.06673527,
-0.017546544,
-0.04074727,
-0.006802272,
0.00074949424,
0.031297088,
0.00086189766,
-0.067903265,
-0.024912907,
... | [
-0.06588581,
-0.0069880905,
-0.04892327,
0.0001806335,
-0.0031904315,
-0.013869999,
0.041490544,
0.041835632,
-0.0074791815,
-0.014029272,
0.01538309,
-0.06673527,
-0.017546544,
-0.04074727,
-0.006802272,
0.00074949424,
0.031297088,
0.00086189766,
-0.067903265,
-0.024912907,
... |
The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. | tients; CD34+ APL patients had a significantly higher percentage of PBLP at presentation; were more frequently female and had a higher proportion of bcr3 expression. Among the 136 APL cases; 24 (17.6%) and 80 (58.8%) were identified as CD34+CD2+ and CD34-CD2-; respectively. The two groups showed statistically significa... | 16531253 | [
-0.0676244,
-0.023753136,
-0.06101529,
-0.002324754,
-0.014936585,
-0.006305089,
0.04190175,
0.063235946,
0.04713616,
-0.008585231,
0.028921459,
-0.024797374,
-0.057631426,
-0.06767727,
-0.0009550162,
0.035451256,
0.030111097,
-0.025220357,
-0.07233008,
-0.009655908,
-0.03751... | [
-0.0676244,
-0.023753136,
-0.06101529,
-0.002324754,
-0.014936585,
-0.006305089,
0.04190175,
0.063235946,
0.04713616,
-0.008585231,
0.028921459,
-0.024797374,
-0.057631426,
-0.06767727,
-0.0009550162,
0.035451256,
0.030111097,
-0.025220357,
-0.07233008,
-0.009655908,
-0.03751... |
The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. | ompared to the M3v cases. There were no differences between the two groups in terms of complete remission; overall survival and disease-free survival.Our findings suggest that immunophenotypic analysis can distinguish a subset of APL patients with different biological characteristics. | 16531253 | [
-0.06528603,
-0.0036396163,
0.0027881465,
0.013075906,
-0.027126828,
-0.023707593,
0.032910146,
0.04720148,
-0.007846879,
-0.049472068,
-0.021730846,
-0.027754579,
-0.026966551,
-0.017042754,
-0.045678854,
0.0811,
0.04738847,
0.005826725,
-0.056257114,
-0.007826844,
-0.094242... | [
-0.06528603,
-0.0036396163,
0.0027881465,
0.013075906,
-0.027126828,
-0.023707593,
0.032910146,
0.04720148,
-0.007846879,
-0.049472068,
-0.021730846,
-0.027754579,
-0.026966551,
-0.017042754,
-0.045678854,
0.0811,
0.04738847,
0.005826725,
-0.056257114,
-0.007826844,
-0.094242... |
The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. | The NK-like homeobox gene (NKX2-5/CSX) plays a crucial role in cardiac development but is not normally expressed in hematopoietic cells. Here; we describe for the first time a fusion between NKX2-5 and the T-cell receptor delta locus (TRD) resulting in NKX2-5 activation in a case of T-cell acute lymphoblastic leukemia ... | 16531254 | [
-0.042368397,
0.023053393,
-0.02382228,
0.01443654,
-0.012858994,
-0.01796282,
0.049102798,
0.034573458,
-0.06007934,
-0.034149244,
0.014529337,
-0.01447631,
-0.0041924296,
-0.017392784,
-0.0028037908,
-0.016902287,
-0.019686192,
0.03809974,
-0.05631444,
0.014303974,
-0.05981... | [
-0.042368397,
0.023053393,
-0.02382228,
0.01443654,
-0.012858994,
-0.01796282,
0.049102798,
0.034573458,
-0.06007934,
-0.034149244,
0.014529337,
-0.01447631,
-0.0041924296,
-0.017392784,
-0.0028037908,
-0.016902287,
-0.019686192,
0.03809974,
-0.05631444,
0.014303974,
-0.05981... |
The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. | ers. Expression of NKX2-5 was analyzed by real-time quantitative PCR in the T-ALL case with the NKX2-5-TRD rearrangement; 18 other cases of T-ALL; three T-ALL derived cell lines; two non-hematopoietic cell lines; peripheral blood mononuclear cells from six healthy individuals and sorted thymocyte subsets.Sequence analy... | 16531254 | [
-0.062237047,
0.0003236681,
-0.018620752,
0.0068519064,
0.019681009,
0.020052098,
0.038222242,
0.028176311,
-0.071567304,
-0.030641409,
0.028732946,
-0.03159564,
-0.012000776,
0.0011861618,
-0.007342275,
-0.004953385,
-0.009217603,
-0.022079838,
-0.038937915,
0.0137170665,
-0... | [
-0.062237047,
0.0003236681,
-0.018620752,
0.0068519064,
0.019681009,
0.020052098,
0.038222242,
0.028176311,
-0.071567304,
-0.030641409,
0.028732946,
-0.03159564,
-0.012000776,
0.0011861618,
-0.007342275,
-0.004953385,
-0.009217603,
-0.022079838,
-0.038937915,
0.0137170665,
-0... |
The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. | the NKX2-5/CSX gene. As a result of this recombination NKX2-5 was placed under influence of the TRD enhancer; resulting in strong ectopic NKX2-5 expression. High NKX2-5 expression was also found in the T-cell lines PEER and CCRF-CEM; which harbor an NKX2-5-BCL11B rearrangement; and in the embryonic kidney cell line 293... | 16531254 | [
-0.06306567,
-0.02303708,
-0.0068112523,
0.00085182267,
-0.00089385203,
0.021718772,
0.05377094,
0.057472855,
-0.06887155,
-0.027511334,
0.031639364,
-0.026619146,
0.029242443,
-0.0060722013,
-0.03645984,
0.024674976,
0.0023652955,
0.010506506,
-0.087247945,
0.0016686902,
-0.... | [
-0.06306567,
-0.02303708,
-0.0068112523,
0.00085182267,
-0.00089385203,
0.021718772,
0.05377094,
0.057472855,
-0.06887155,
-0.027511334,
0.031639364,
-0.026619146,
0.029242443,
-0.0060722013,
-0.03645984,
0.024674976,
0.0023652955,
0.010506506,
-0.087247945,
0.0016686902,
-0.... |
The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. | sion of yet another homeobox gene in T-ALL further supports the hypothesis that homeobox genes play an important role in malignant transformation of particular types of T-ALL. | 16531254 | [
-0.03044276,
-0.015500793,
-0.00567808,
-0.009599848,
0.010012315,
-0.011489214,
0.095905334,
0.02746235,
-0.08701733,
-0.03305062,
0.034886762,
-0.055935908,
0.04393444,
-0.018255012,
0.031906355,
0.026171725,
-0.027781678,
0.033875555,
-0.07514891,
-0.038000226,
-0.02224663... | [
-0.03044276,
-0.015500793,
-0.00567808,
-0.009599848,
0.010012315,
-0.011489214,
0.095905334,
0.02746235,
-0.08701733,
-0.03305062,
0.034886762,
-0.055935908,
0.04393444,
-0.018255012,
0.031906355,
0.026171725,
-0.027781678,
0.033875555,
-0.07514891,
-0.038000226,
-0.02224663... |
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. | Campath-1H is used in conditioning regimens and more recently as an anti-leukemic therapy in acute lymphoblastic leukemias (ALL). We therefore investigated CD52 expression and campath-1H-mediated lysis of ALL cells in vitro.Complement-mediated cytotoxicity assays were performed on freshly isolated neoplastic cells and ... | 16531255 | [
-0.03448014,
0.0179185,
-0.026059642,
-0.018969398,
-0.02129734,
-0.025594056,
0.08130502,
0.012424557,
-0.06523558,
-0.037779167,
0.029824257,
-0.05704122,
-0.021749625,
-0.027403198,
-0.010881464,
-0.031340744,
-0.00007254032,
0.027536223,
-0.0284674,
0.008952598,
-0.062415... | [
-0.03448014,
0.0179185,
-0.026059642,
-0.018969398,
-0.02129734,
-0.025594056,
0.08130502,
0.012424557,
-0.06523558,
-0.037779167,
0.029824257,
-0.05704122,
-0.021749625,
-0.027403198,
-0.010881464,
-0.031340744,
-0.00007254032,
0.027536223,
-0.0284674,
0.008952598,
-0.062415... |
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. | 1 freshly isolated ALL samples CD52 was expressed at varying levels in 87% of cases. Whereas ADCC was equivalent in different CD52+ lines; complement-dependent cytotoxicity (CDC) was variable. The REH cell line bearing the t(12;21) translocation showed 47-60% lysis when treated with 10 microg/mL campath-1H compared to ... | 16531255 | [
-0.057541274,
0.009486355,
-0.0041299784,
0.004497898,
-0.019595854,
-0.03746812,
0.07811825,
0.059450477,
-0.04765054,
-0.020855397,
0.040199343,
-0.045873918,
-0.00863782,
-0.032642078,
-0.015803963,
-0.011289492,
0.014451611,
0.022963477,
-0.017328674,
0.028638054,
-0.0088... | [
-0.057541274,
0.009486355,
-0.0041299784,
0.004497898,
-0.019595854,
-0.03746812,
0.07811825,
0.059450477,
-0.04765054,
-0.020855397,
0.040199343,
-0.045873918,
-0.00863782,
-0.032642078,
-0.015803963,
-0.011289492,
0.014451611,
0.022963477,
-0.017328674,
0.028638054,
-0.0088... |
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. | %)(p<0.0001). In t(12;21) samples; efficient CDC was obtained with as little as 1 microg/mL campath-1H. CDC correlated in part with CD52 levels; suggesting that CD52 expression and other yet undefined factors contribute to the particular sensitivity of t(12;21) cells. The resistance of non t(12;21) ALL cases could be o... | 16531255 | [
-0.07443918,
0.049981356,
-0.026109664,
0.01229552,
-0.0005428412,
0.0057048285,
0.06985667,
0.066925995,
-0.07278735,
-0.052219328,
0.0135677,
-0.06260991,
-0.009178346,
-0.03031918,
0.030665534,
-0.0076464014,
0.0046491185,
-0.0041562323,
-0.029386694,
0.026402732,
-0.08189... | [
-0.07443918,
0.049981356,
-0.026109664,
0.01229552,
-0.0005428412,
0.0057048285,
0.06985667,
0.066925995,
-0.07278735,
-0.052219328,
0.0135677,
-0.06260991,
-0.009178346,
-0.03031918,
0.030665534,
-0.0076464014,
0.0046491185,
-0.0041562323,
-0.029386694,
0.026402732,
-0.08189... |
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. | nclude that most ALL samples express CD52 to a variable level and that campath-1H has cytotoxic activity against CD52+ALL; alone or in combination with cytotoxic drugs. | 16531255 | [
-0.06088032,
0.03864994,
0.0045546954,
-0.0402759,
-0.033745397,
-0.021524018,
0.10251563,
0.028974127,
-0.065784864,
-0.030173607,
0.024202859,
0.027721336,
0.059814114,
-0.0319595,
0.012181395,
-0.042328347,
0.0030770015,
0.02244362,
-0.0019908051,
-0.033052363,
-0.02516244... | [
-0.06088032,
0.03864994,
0.0045546954,
-0.0402759,
-0.033745397,
-0.021524018,
0.10251563,
0.028974127,
-0.065784864,
-0.030173607,
0.024202859,
0.027721336,
0.059814114,
-0.0319595,
0.012181395,
-0.042328347,
0.0030770015,
0.02244362,
-0.0019908051,
-0.033052363,
-0.02516244... |
Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a single tumor cell clone. | B-cell chronic lymphoproliferative disorders (B-CLPD) are usually monoclonal expansions of a single B-cell clone. However in some cases; two unrelated B-cell clones co-exist. Additionally; cases with two B-cell subpopulations displaying a similar phenotype but distinct DNA contents exist; the exact nature of these case... | 16531256 | [
-0.074331485,
-0.032009028,
-0.028829502,
0.044940893,
-0.02677216,
-0.049055573,
0.04747917,
0.044620268,
0.0019922147,
-0.06113244,
0.030245595,
-0.06888086,
0.031287625,
-0.026424816,
-0.0013960532,
-0.0005013935,
0.0017484064,
-0.053036664,
-0.030112,
0.008670226,
-0.0405... | [
-0.074331485,
-0.032009028,
-0.028829502,
0.044940893,
-0.02677216,
-0.049055573,
0.04747917,
0.044620268,
0.0019922147,
-0.06113244,
0.030245595,
-0.06888086,
0.031287625,
-0.026424816,
-0.0013960532,
-0.0005013935,
0.0017484064,
-0.053036664,
-0.030112,
0.008670226,
-0.0405... |
Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a single tumor cell clone. | (group A; n= 9) and the other; two B-cell subsets showing different DNA contents and/or light scatter properties; but a similar immunophenotype (group B; n= 7).Fluorescent in situ hybridization studies revealed the presence of genetic abnormalities in six cases from group A; either in one (n=5) or the two co-existing ... | 16531256 | [
-0.030859511,
-0.012816008,
-0.046076443,
0.0055467314,
0.010328625,
0.041181486,
0.028172607,
0.01888815,
-0.0020417823,
-0.05246117,
0.048603732,
-0.056079183,
0.01001604,
-0.010960448,
-0.047858845,
0.012031219,
0.02645671,
-0.08470404,
-0.049641248,
-0.0019786002,
-0.0168... | [
-0.030859511,
-0.012816008,
-0.046076443,
0.0055467314,
0.010328625,
0.041181486,
0.028172607,
0.01888815,
-0.0020417823,
-0.05246117,
0.048603732,
-0.056079183,
0.01001604,
-0.010960448,
-0.047858845,
0.012031219,
0.02645671,
-0.08470404,
-0.049641248,
-0.0019786002,
-0.0168... |
Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: biclonality versus intraclonal evolution of a single tumor cell clone. | ents had additional chromosomal abnormalities as compared to the other subset; molecular analysis confirmed the monoclonal nature of these cases.In summary; we show that in group A; two phenotypically/cytogenetically distinct; unrelated B-cell clones co-exist; while the two B-cell populations from group B appear to rep... | 16531256 | [
-0.050188232,
-0.00639667,
-0.06320789,
0.013472279,
-0.028462186,
0.009585021,
0.04459697,
0.030405816,
0.02763681,
-0.009218926,
0.026145807,
-0.063846886,
0.015775347,
0.0016990114,
-0.016081534,
0.010729898,
-0.026092555,
-0.06192988,
-0.057723124,
-0.016068222,
-0.047712... | [
-0.050188232,
-0.00639667,
-0.06320789,
0.013472279,
-0.028462186,
0.009585021,
0.04459697,
0.030405816,
0.02763681,
-0.009218926,
0.026145807,
-0.063846886,
0.015775347,
0.0016990114,
-0.016081534,
0.010729898,
-0.026092555,
-0.06192988,
-0.057723124,
-0.016068222,
-0.047712... |
The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. | The development of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT) for B-lineage acute lymphoblastic leukemia (B-ALL) is associated with a lower probability of leukemia relapse. However; mechanisms by which this GVHD-associated graft-versus-leukemia effect is exerted are poorly underst... | 16531257 | [
-0.060659412,
0.018280735,
-0.04656439,
-0.01936394,
-0.02802957,
0.025863161,
0.021891415,
0.070822805,
-0.0062117055,
-0.046858594,
0.038433675,
0.020353533,
0.0041924,
-0.04161642,
-0.093610205,
0.003376654,
0.002873499,
0.011848377,
-0.09516146,
0.011908555,
-0.07579752,
... | [
-0.060659412,
0.018280735,
-0.04656439,
-0.01936394,
-0.02802957,
0.025863161,
0.021891415,
0.070822805,
-0.0062117055,
-0.046858594,
0.038433675,
0.020353533,
0.0041924,
-0.04161642,
-0.093610205,
0.003376654,
0.002873499,
0.011848377,
-0.09516146,
0.011908555,
-0.07579752,
... |
The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. | flow-cytometry to quantify pro-B (CD19+CD10+CD34+); pre-B (CD19+CD10+CD34-) precursors and malignant lymphoblasts identified by leukemia-associated markers in 161 prospective marrow samples from 39 consecutive B-ALL patients after allogeneic SCT. Chimerism analysis was performed by quantitative real-time polymerase cha... | 16531257 | [
-0.08499518,
0.040281948,
-0.06492094,
-0.010077161,
0.0072875894,
0.011585399,
0.078161396,
0.04578101,
-0.0015991654,
-0.042550977,
0.021689253,
0.002410844,
-0.026854632,
-0.030618552,
-0.068658166,
0.049438152,
0.039080698,
0.014294887,
-0.065134495,
0.03192658,
-0.027201... | [
-0.08499518,
0.040281948,
-0.06492094,
-0.010077161,
0.0072875894,
0.011585399,
0.078161396,
0.04578101,
-0.0015991654,
-0.042550977,
0.021689253,
0.002410844,
-0.026854632,
-0.030618552,
-0.068658166,
0.049438152,
0.039080698,
0.014294887,
-0.065134495,
0.03192658,
-0.027201... |
The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. | days +30 and +60 post-SCT. Patients who develop chronic GVHD have lower percentages of marrow B-cell precursors during the first year after SCT. Likewise; recipient-derived leukemia B cells were absent at days +30 and +60 in patients with acute GVHD grades II-IV and were less likely to be detected in patients with chr... | 16531257 | [
-0.03921212,
0.036191687,
0.0011000843,
-0.00525568,
-0.033812765,
0.002701346,
0.0163317,
0.02274677,
-0.012643035,
-0.04856743,
0.03255648,
0.016692547,
0.03760835,
0.006511965,
-0.063723035,
0.022051804,
0.033492014,
-0.059660155,
-0.03359893,
0.023441736,
-0.07318526,
-... | [
-0.03921212,
0.036191687,
0.0011000843,
-0.00525568,
-0.033812765,
0.002701346,
0.0163317,
0.02274677,
-0.012643035,
-0.04856743,
0.03255648,
0.016692547,
0.03760835,
0.006511965,
-0.063723035,
0.022051804,
0.033492014,
-0.059660155,
-0.03359893,
0.023441736,
-0.07318526,
-... |
The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. | de that the development of GVHD after allogeneic SCT is associated with a non-specific inhibition of B-lymphopoiesis. | 16531257 | [
-0.031563967,
0.06884234,
-0.05188782,
-0.008874839,
-0.072939456,
-0.026240412,
0.034636807,
0.068357155,
-0.03328907,
-0.07272381,
0.029650183,
0.049300168,
0.040998116,
-0.009157863,
-0.10533902,
0.016819742,
0.026617778,
0.018841345,
-0.09811515,
0.016455851,
-0.0892201,
... | [
-0.031563967,
0.06884234,
-0.05188782,
-0.008874839,
-0.072939456,
-0.026240412,
0.034636807,
0.068357155,
-0.03328907,
-0.07272381,
0.029650183,
0.049300168,
0.040998116,
-0.009157863,
-0.10533902,
0.016819742,
0.026617778,
0.018841345,
-0.09811515,
0.016455851,
-0.0892201,
... |
Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. | The ability of acute myeloid leukemic (AML) blasts to differentiate into leukemic dendritic cells (DC) thus acquiring the potential to present known and unknown leukemic antigens efficiently; holds promise as a possible new treatment for AML patients with minimal residual disease. Recent advances in culture methods hav... | 16531258 | [
-0.0897139,
-0.035515107,
-0.015717382,
-0.0023220384,
-0.03331387,
-0.0034763466,
0.046172325,
0.041045047,
-0.013771164,
-0.044346906,
0.037877414,
-0.028481882,
0.014683872,
0.011637037,
-0.04219936,
0.033474933,
0.026173266,
0.02233452,
-0.051299598,
0.027918149,
-0.07226... | [
-0.0897139,
-0.035515107,
-0.015717382,
-0.0023220384,
-0.03331387,
-0.0034763466,
0.046172325,
0.041045047,
-0.013771164,
-0.044346906,
0.037877414,
-0.028481882,
0.014683872,
0.011637037,
-0.04219936,
0.033474933,
0.026173266,
0.02233452,
-0.051299598,
0.027918149,
-0.07226... |
Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. | s immune system. This review describes ways to improve AML-DC vaccines and discusses critical aspects concerning the development of clinical vaccination protocols. | 16531258 | [
-0.06603665,
0.0050226464,
-0.0025379509,
-0.017547643,
-0.003428314,
0.017880488,
0.0031087818,
0.07711377,
-0.026694251,
-0.0039808387,
0.008953558,
-0.020356864,
0.052669555,
0.019850938,
-0.0065637236,
0.0010268299,
0.033044953,
0.009585965,
-0.03504203,
0.056237664,
-0.0... | [
-0.06603665,
0.0050226464,
-0.0025379509,
-0.017547643,
-0.003428314,
0.017880488,
0.0031087818,
0.07711377,
-0.026694251,
-0.0039808387,
0.008953558,
-0.020356864,
0.052669555,
0.019850938,
-0.0065637236,
0.0010268299,
0.033044953,
0.009585965,
-0.03504203,
0.056237664,
-0.0... |
Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. | The immunophenotypic analysis of ex vivo-expanded mesenchymal stromal cells (MSC) has so far been confined to single or dual staining analysis in normal subjects. In this study; using a four-color cytofluorimetric protocol; we demonstrated that cultured MSC derived from the bone marrow of patients with hematologic mali... | 16531259 | [
-0.072468914,
0.05991903,
0.01289701,
0.0049899146,
-0.000032595075,
-0.016034482,
0.03471245,
0.075459525,
-0.0036014167,
-0.010573946,
0.025767319,
-0.039011452,
-0.027022306,
0.011101308,
-0.022896865,
0.007129403,
0.00378833,
0.031054292,
-0.100559294,
-0.015834218,
-0.04... | [
-0.072468914,
0.05991903,
0.01289701,
0.0049899146,
-0.000032595075,
-0.016034482,
0.03471245,
0.075459525,
-0.0036014167,
-0.010573946,
0.025767319,
-0.039011452,
-0.027022306,
0.011101308,
-0.022896865,
0.007129403,
0.00378833,
0.031054292,
-0.100559294,
-0.015834218,
-0.04... |
Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. | genesis. This paper provides evidence that multiparametric flow cytometry is essential for the establishment of a standardized protocol to identify various MSCs subsets and aberrant phenotypes. | 16531259 | [
-0.023985432,
-0.021354176,
-0.036361597,
0.0017866767,
-0.04667507,
0.008535059,
0.051540915,
0.09324436,
0.03599137,
-0.0003437824,
0.03509225,
-0.013539737,
-0.007543379,
-0.009883744,
0.0059765247,
0.0062244446,
0.04540572,
0.03416668,
-0.03421957,
0.009539961,
-0.0117481... | [
-0.023985432,
-0.021354176,
-0.036361597,
0.0017866767,
-0.04667507,
0.008535059,
0.051540915,
0.09324436,
0.03599137,
-0.0003437824,
0.03509225,
-0.013539737,
-0.007543379,
-0.009883744,
0.0059765247,
0.0062244446,
0.04540572,
0.03416668,
-0.03421957,
0.009539961,
-0.0117481... |
Multilineage engraftment of refrozen cord blood hematopoietic progenitors in NOD/SCID mice. | Seven cord blood (CB) units were tested for their capacity to repopulate irradiated NOD/SCID mice after one or two successive cryopreservation procedures. In primary transplants with frozen or refrozen CB cells we observed equivalent human colonies and percentages of human CD45+ cells; with multilineage engraftment. In... | 16531260 | [
-0.08603842,
-0.0165745,
-0.014565874,
0.011207076,
0.010814662,
-0.025141098,
0.03828364,
0.0693309,
-0.014432852,
-0.012730175,
0.08252665,
-0.068213515,
-0.0049118255,
-0.02355814,
0.0006393354,
-2.0784637e-7,
-0.028386826,
0.03461224,
-0.12802006,
0.022613686,
-0.03016931... | [
-0.08603842,
-0.0165745,
-0.014565874,
0.011207076,
0.010814662,
-0.025141098,
0.03828364,
0.0693309,
-0.014432852,
-0.012730175,
0.08252665,
-0.068213515,
-0.0049118255,
-0.02355814,
0.0006393354,
-2.0784637e-7,
-0.028386826,
0.03461224,
-0.12802006,
0.022613686,
-0.03016931... |
Multilineage engraftment of refrozen cord blood hematopoietic progenitors in NOD/SCID mice. | nly been stored in individual bags; our results suggest new options for optimizing the timing of infusions of expanded and non-expanded progenitors in transplants. | 16531260 | [
-0.06492057,
0.019139823,
0.0015866433,
0.021889336,
0.0031382502,
0.025946872,
0.0295773,
0.033528056,
-0.036864847,
0.0027962294,
0.024438644,
0.0020004052,
-0.02553311,
0.010130492,
-0.0328607,
0.0014540058,
-0.023757938,
-0.034996245,
-0.09166827,
0.01609667,
-0.027054686... | [
-0.06492057,
0.019139823,
0.0015866433,
0.021889336,
0.0031382502,
0.025946872,
0.0295773,
0.033528056,
-0.036864847,
0.0027962294,
0.024438644,
0.0020004052,
-0.02553311,
0.010130492,
-0.0328607,
0.0014540058,
-0.023757938,
-0.034996245,
-0.09166827,
0.01609667,
-0.027054686... |
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. | We report on the outcomes of 53 patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia secondary to MDS; autografted in first complete remission. Five (9.4%) died from the procedure whereas hematological reconstitution occurred in all the remaining patients. Forty patients (75%) relapsed; with 87.5% of... | 16531261 | [
-0.077804245,
-0.0058513493,
-0.023445474,
-0.028562065,
-0.07555989,
0.042322088,
-0.004755891,
0.03267671,
-0.027186064,
-0.007861916,
0.013639789,
0.007000244,
0.0037906857,
-0.046410017,
-0.043791603,
0.077911116,
-0.0151761025,
0.0322225,
-0.044486284,
0.017901389,
-0.08... | [
-0.077804245,
-0.0058513493,
-0.023445474,
-0.028562065,
-0.07555989,
0.042322088,
-0.004755891,
0.03267671,
-0.027186064,
-0.007861916,
0.013639789,
0.007000244,
0.0037906857,
-0.046410017,
-0.043791603,
0.077911116,
-0.0151761025,
0.0322225,
-0.044486284,
0.017901389,
-0.08... |
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. | after autograft; respectively. Karyotype was the only prognostic factor for disease-free and overall survival. The eight survivors (15%); including two patients with unfavorable or intermediate karyotype; remained in first complete remission 50+ to 119+ months after transplantation and are probably cured. | 16531261 | [
-0.026902398,
0.016494608,
0.024481049,
0.024828866,
-0.045323383,
0.0072774263,
0.02425363,
0.044092644,
-0.06571088,
0.009578377,
0.03697575,
-0.009391091,
0.022527916,
-0.055436864,
-0.057470266,
0.11001756,
-0.033230014,
0.0374841,
-0.06640652,
0.010508122,
-0.05500878,
... | [
-0.026902398,
0.016494608,
0.024481049,
0.024828866,
-0.045323383,
0.0072774263,
0.02425363,
0.044092644,
-0.06571088,
0.009578377,
0.03697575,
-0.009391091,
0.022527916,
-0.055436864,
-0.057470266,
0.11001756,
-0.033230014,
0.0374841,
-0.06640652,
0.010508122,
-0.05500878,
... |
The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. | To verify the potential clinical and prognostic value of BCR/ABL isoforms; we analyzed 101 consecutive adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia enrolled in the GIMEMA 0496 trial between October 1996 and December 1999. A p190 or p210 with or without p190 BCR/ABL transcript was do... | 16531262 | [
-0.08703642,
0.037149042,
-0.03885459,
-0.032218933,
-0.024477327,
0.019707114,
0.040187053,
0.06257242,
-0.0057495735,
-0.052205864,
0.021292744,
-0.033231605,
-0.051859424,
-0.012898233,
-0.051033296,
-0.005073349,
0.019587193,
0.017628472,
-0.009620376,
0.019240752,
-0.032... | [
-0.08703642,
0.037149042,
-0.03885459,
-0.032218933,
-0.024477327,
0.019707114,
0.040187053,
0.06257242,
-0.0057495735,
-0.052205864,
0.021292744,
-0.033231605,
-0.051859424,
-0.012898233,
-0.051033296,
-0.005073349,
0.019587193,
0.017628472,
-0.009620376,
0.019240752,
-0.032... |
The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. | ranscript (p<0.05; p=0.009 and p=0.03; respectively). A complete remission was achieved in 62/92 (67.4%) patients; while 16/92 (17.4%) were resistant and 14/92 (15.2%) died of therapy-related complications. Fifty-two patients underwent intensive re-induction treatment; which was followed by stem cell transplant consoli... | 16531262 | [
-0.04339641,
0.038990412,
-0.037265174,
0.0030623002,
-0.0618432,
0.011041532,
-0.03150553,
0.05653477,
-0.009462275,
-0.025905134,
0.027311869,
-0.030231504,
-0.044670433,
-0.02658196,
-0.0346375,
0.03896387,
-0.006582452,
-0.019694272,
-0.06688621,
0.031956743,
-0.03699975,... | [
-0.04339641,
0.038990412,
-0.037265174,
0.0030623002,
-0.0618432,
0.011041532,
-0.03150553,
0.05653477,
-0.009462275,
-0.025905134,
0.027311869,
-0.030231504,
-0.044670433,
-0.02658196,
-0.0346375,
0.03896387,
-0.006582452,
-0.019694272,
-0.06688621,
0.031956743,
-0.03699975,... |
The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. | contrast; the p190 emerged as the only independent prognostic factor favorably affecting the 5-year overall survival and disease-free survival rates (p=0.008 and p=0.02; respectively). | 16531262 | [
-0.047723256,
0.028606992,
0.0037814616,
-0.0021148548,
0.027932934,
-0.0018452319,
0.052738246,
0.08331348,
-0.0059182234,
-0.019952096,
0.062983915,
0.016163895,
-0.023214534,
-0.024778347,
-0.08913734,
-0.006400174,
-0.046159446,
-0.00411512,
-0.007461814,
-0.022729212,
-0... | [
-0.047723256,
0.028606992,
0.0037814616,
-0.0021148548,
0.027932934,
-0.0018452319,
0.052738246,
0.08331348,
-0.0059182234,
-0.019952096,
0.062983915,
0.016163895,
-0.023214534,
-0.024778347,
-0.08913734,
-0.006400174,
-0.046159446,
-0.00411512,
-0.007461814,
-0.022729212,
-0... |
Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. | The expression of proteins of the tumor necrosis factor (TNF) family on erythroblasts was measured during thalidomide treatment in 29 patients with multiple myeloma (MM). A clinical response was observed in 17 patients (58.6%) and haemoglobin concentration increased in 22 patients (75.9%). The expression of FasL; Fas; ... | 16531263 | [
-0.096938804,
0.015947739,
-0.006928007,
0.021916484,
-0.011484504,
0.0293108,
0.0390633,
0.06880044,
-0.04199438,
0.02875123,
0.033041265,
-0.077007465,
-0.0015155015,
0.0041068424,
0.0011324628,
0.035412773,
0.0053092516,
0.030589815,
-0.10519912,
0.047430202,
-0.07066567,
... | [
-0.096938804,
0.015947739,
-0.006928007,
0.021916484,
-0.011484504,
0.0293108,
0.0390633,
0.06880044,
-0.04199438,
0.02875123,
0.033041265,
-0.077007465,
-0.0015155015,
0.0041068424,
0.0011324628,
0.035412773,
0.0053092516,
0.030589815,
-0.10519912,
0.047430202,
-0.07066567,
... |
Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts. | throblasts and the expression of FasL; TRAIL; TRAIL-R1 and TRAIL-R2 was lower in cultures with thalidomide than in control cultures. Altogether our results suggest that thalidomide may stimulate erythropoiesis in MM patients by decreasing the expression of TNF-like ligands/receptors on erythroblasts. | 16531263 | [
-0.06082797,
0.02242931,
-0.013160669,
0.04330716,
-0.049004767,
0.019727629,
-0.0115757715,
0.060239483,
-0.07821503,
0.017239941,
0.00097300677,
-0.03571035,
0.009068022,
0.012277941,
-0.00060102396,
-0.007777367,
0.018858276,
0.021412836,
-0.11684106,
0.03814454,
-0.076877... | [
-0.06082797,
0.02242931,
-0.013160669,
0.04330716,
-0.049004767,
0.019727629,
-0.0115757715,
0.060239483,
-0.07821503,
0.017239941,
0.00097300677,
-0.03571035,
0.009068022,
0.012277941,
-0.00060102396,
-0.007777367,
0.018858276,
0.021412836,
-0.11684106,
0.03814454,
-0.076877... |
Hyperhomocysteinemia and functional cobalamin deficiency due to granulocytosis-induced alterations in the cobalamin-binding protein. | Serum cobalamin and homocysteine levels were studied in patients with chronic myelogenous leukemia (CML) and in stem cell donors treated with granulocyte-colony stimulating factor (G-CSF). Cytoreductive treatment in patients with CML resulted in a decrease of cobalamin and homocysteine levels. In stem cell donors cobal... | 16531264 | [
-0.02770498,
0.08890126,
-0.038904298,
-0.020345429,
-0.004039754,
0.003626446,
0.040530868,
0.0011782616,
-0.051303543,
-0.0010691016,
0.02643839,
-0.042317424,
0.033651285,
0.04007756,
-0.017852247,
-0.0013774162,
0.010552691,
0.034904543,
-0.1336452,
0.03895763,
-0.0596763... | [
-0.02770498,
0.08890126,
-0.038904298,
-0.020345429,
-0.004039754,
0.003626446,
0.040530868,
0.0011782616,
-0.051303543,
-0.0010691016,
0.02643839,
-0.042317424,
0.033651285,
0.04007756,
-0.017852247,
-0.0013774162,
0.010552691,
0.034904543,
-0.1336452,
0.03895763,
-0.0596763... |
Hyperhomocysteinemia and functional cobalamin deficiency due to granulocytosis-induced alterations in the cobalamin-binding protein. | balamin. We hypothesize that the increased homocysteine levels in patients with CML and donors treated with G-CSF may be the result of a functional methylcobalamin deficiency due to decreased transcobalamin levels. | 16531264 | [
-0.018042317,
0.06264952,
-0.037946034,
-0.0039288905,
-0.008967975,
-0.0002887668,
0.0573844,
0.04738601,
-0.055150717,
-0.020355774,
0.04903468,
-0.06381954,
0.029702678,
0.05855443,
-0.00014137109,
0.009353551,
0.027149895,
0.044062074,
-0.124660835,
-0.002941682,
-0.08259... | [
-0.018042317,
0.06264952,
-0.037946034,
-0.0039288905,
-0.008967975,
-0.0002887668,
0.0573844,
0.04738601,
-0.055150717,
-0.020355774,
0.04903468,
-0.06381954,
0.029702678,
0.05855443,
-0.00014137109,
0.009353551,
0.027149895,
0.044062074,
-0.124660835,
-0.002941682,
-0.08259... |
Prognostic value of donor cytotoxic T-lymphocyte precursor frequencies for acute graft-versus-host disease in hematopoietic stem cell transplantation from HLA-matched siblings: a single center experience in a cohort of 92 patients. | We investigated the prognostic value of cytotoxic T-lymphocyte precursor frequencies (CTL-p-f) for the development of graft-versus-host disease (GvHD) in a cohort of 92 recipients of a hematopoietic stem cell transplantation from HLA-matched sibling donors. CTL-p-f and clinical variables were correlated with acute GvHD... | 16531265 | [
-0.06939962,
0.030231906,
0.0028894213,
0.0003041166,
-0.024038378,
0.031462587,
0.05013681,
0.09149834,
0.025844267,
-0.026192067,
-0.010795198,
-0.034833577,
0.0056852037,
-0.050163563,
-0.06372779,
0.019008646,
-0.012387056,
0.021443252,
-0.066082135,
0.005334059,
-0.01793... | [
-0.06939962,
0.030231906,
0.0028894213,
0.0003041166,
-0.024038378,
0.031462587,
0.05013681,
0.09149834,
0.025844267,
-0.026192067,
-0.010795198,
-0.034833577,
0.0056852037,
-0.050163563,
-0.06372779,
0.019008646,
-0.012387056,
0.021443252,
-0.066082135,
0.005334059,
-0.01793... |
Prognostic value of donor cytotoxic T-lymphocyte precursor frequencies for acute graft-versus-host disease in hematopoietic stem cell transplantation from HLA-matched siblings: a single center experience in a cohort of 92 patients. | c GvHD was observed. In summary CTL-p-f may be considered as a functional assay useful for identifying patients at high risk of severe GVHD. | 16531265 | [
-0.025253046,
0.044096418,
0.008404384,
-0.04034636,
0.02010669,
0.037420787,
0.08680984,
0.07287346,
-0.04133042,
-0.06750103,
-0.006027353,
-0.046543267,
0.019308805,
0.016901854,
-0.1029803,
0.015399172,
0.020266268,
0.026649345,
-0.003959502,
0.00933525,
-0.02577167,
-0... | [
-0.025253046,
0.044096418,
0.008404384,
-0.04034636,
0.02010669,
0.037420787,
0.08680984,
0.07287346,
-0.04133042,
-0.06750103,
-0.006027353,
-0.046543267,
0.019308805,
0.016901854,
-0.1029803,
0.015399172,
0.020266268,
0.026649345,
-0.003959502,
0.00933525,
-0.02577167,
-0... |
The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. | The influence of BK-viruria; donor background; and conditioning on the development of hemorrhagic cystitis was examined in 90 allogeneic hematopoetic stem cell transplant patients; of whom 15 developed hemorrhagic cystitis. Thirty-two patients had related and 58 had unrelated donors; while 44 received full; and 46 rece... | 16531266 | [
-0.02093838,
0.0187728,
-0.0039292676,
0.07339062,
-0.006553208,
-0.04929022,
0.037678454,
0.06616315,
-0.014361922,
0.0036668736,
0.042620763,
-0.026823977,
-0.017643508,
0.0053674527,
-0.07668549,
-0.0009748437,
0.0063173855,
-0.010542261,
-0.11319479,
0.05423253,
-0.039219... | [
-0.02093838,
0.0187728,
-0.0039292676,
0.07339062,
-0.006553208,
-0.04929022,
0.037678454,
0.06616315,
-0.014361922,
0.0036668736,
0.042620763,
-0.026823977,
-0.017643508,
0.0053674527,
-0.07668549,
-0.0009748437,
0.0063173855,
-0.010542261,
-0.11319479,
0.05423253,
-0.039219... |
The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. | with related donors than in those with unrelated donors (p=0.02). Finally; hemorrhagic cystitis and BK-viruria were less common in patients receiving RIC; rather than full conditioning (p<0.01 and p<0.01; respectively). | 16531266 | [
-0.011570717,
0.0033346396,
-0.036473345,
0.08272963,
-0.003004,
-0.063216925,
0.032219894,
0.059707824,
0.00034040073,
-0.001045917,
0.051387012,
-0.02762085,
0.0024989028,
0.03128945,
-0.048489347,
-0.011231771,
0.03865324,
-0.03296425,
-0.07145798,
0.06295108,
-0.015937151... | [
-0.011570717,
0.0033346396,
-0.036473345,
0.08272963,
-0.003004,
-0.063216925,
0.032219894,
0.059707824,
0.00034040073,
-0.001045917,
0.051387012,
-0.02762085,
0.0024989028,
0.03128945,
-0.048489347,
-0.011231771,
0.03865324,
-0.03296425,
-0.07145798,
0.06295108,
-0.015937151... |
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. | Acute graft-versus-host disease (GVHD) is a major cause of mortality after allogeneic hematopoietic stem cell transplantation. We performed a phase II study on patients with acute steroid-refractory GVHD grades II to IV given extracorporeal photochemotherapy (ECP) weekly and analyzed response and long-term survival. Co... | 16531267 | [
-0.054427866,
0.0023264496,
0.0017058955,
0.027682908,
-0.008944018,
-0.010424638,
0.012126347,
0.07358883,
-0.055365816,
0.00010698486,
0.020031922,
-0.03392697,
0.013345681,
-0.0077246837,
-0.05081006,
0.04660269,
0.010511734,
0.0026245837,
-0.034623735,
0.0389919,
-0.05027... | [
-0.054427866,
0.0023264496,
0.0017058955,
0.027682908,
-0.008944018,
-0.010424638,
0.012126347,
0.07358883,
-0.055365816,
0.00010698486,
0.020031922,
-0.03392697,
0.013345681,
-0.0077246837,
-0.05081006,
0.04660269,
0.010511734,
0.0026245837,
-0.034623735,
0.0389919,
-0.05027... |
The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. | ts who responded completely to ECP compared to 11% in patients not responding completely. We conclude that intensified ECP is highly effective in acute GVHD and that sustained responses are associated with over 50% long-term survival. | 16531267 | [
-0.06894538,
0.0014982361,
0.03113149,
0.0093938075,
-0.012105217,
-0.012144993,
0.05330008,
0.06809682,
-0.035268214,
-0.031104973,
0.046379026,
0.024594938,
-0.024449091,
-0.008001641,
-0.03198005,
0.022884563,
0.04476146,
-0.022778492,
-0.04216275,
0.03860941,
-0.067301296... | [
-0.06894538,
0.0014982361,
0.03113149,
0.0093938075,
-0.012105217,
-0.012144993,
0.05330008,
0.06809682,
-0.035268214,
-0.031104973,
0.046379026,
0.024594938,
-0.024449091,
-0.008001641,
-0.03198005,
0.022884563,
0.04476146,
-0.022778492,
-0.04216275,
0.03860941,
-0.067301296... |
A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points. | Serial analysis for the activating JAK2(V617F) mutation performed in 44 patients with myelofibrosis with myeloid metaplasia showed no interval change in 88% (22/25) of patients over a median interval of 18.6 months. The increase in JAK2 expression observed in three patients did not correspond to disease progression or ... | 16531268 | [
-0.07557342,
-0.067348465,
-0.01763825,
-0.03364753,
-0.077068865,
-0.012484302,
-0.019440794,
0.06617348,
-0.024861787,
0.027425407,
0.028814036,
-0.022872308,
-0.019948179,
-0.01953426,
-0.044329286,
-0.00903276,
-0.017838532,
-0.02538252,
-0.123374276,
0.013846226,
-0.0855... | [
-0.07557342,
-0.067348465,
-0.01763825,
-0.03364753,
-0.077068865,
-0.012484302,
-0.019440794,
0.06617348,
-0.024861787,
0.027425407,
0.028814036,
-0.022872308,
-0.019948179,
-0.01953426,
-0.044329286,
-0.00903276,
-0.017838532,
-0.02538252,
-0.123374276,
0.013846226,
-0.0855... |
The value of autofluorescence as a diagnostic feature of acute promyelocytic leukemia. | Autofluorescence is an immunophenotypic characteristic of leukemic blasts in acute promyelocytic leukemia (APL). We examined the fluorescent intensity of isotype controls in 25 cases of APML and 25 controls with acute myeloid leukemia. The fluorescence of the FITC- and PE-conjugated controls was consistently higher in ... | 16531269 | [
-0.060642853,
-0.03082326,
0.0026230807,
0.041916467,
-0.00033696435,
0.0023242906,
0.07474707,
0.040490195,
-0.0609598,
-0.06154087,
-0.00023688615,
-0.03499642,
-0.013113753,
0.030453488,
-0.041890055,
0.062438894,
0.0075011193,
-0.0042556967,
-0.049972244,
0.005510285,
-0.... | [
-0.060642853,
-0.03082326,
0.0026230807,
0.041916467,
-0.00033696435,
0.0023242906,
0.07474707,
0.040490195,
-0.0609598,
-0.06154087,
-0.00023688615,
-0.03499642,
-0.013113753,
0.030453488,
-0.041890055,
0.062438894,
0.0075011193,
-0.0042556967,
-0.049972244,
0.005510285,
-0.... |
Molecular response in two children with relapsed acute myeloid leukemia treated with a combination of gemtuzumab ozogamicin and cytarabine. | Phase I/II studies of gemtuzumab ozogamicin (GO) in pediatric refractory/relapsed acute myeloid leukemia (AML) have been reported. We present the cases of two children with relapsed AML who were treated with GO plus cytarabine; leading to a decrease of minimal residual disease down to levels not previously obtained. Th... | 16531270 | [
-0.11059633,
-0.08116085,
-0.046046253,
-0.001254807,
-0.050658878,
0.00023517216,
-0.0035461213,
0.04823258,
-0.09849152,
-0.032368354,
0.0070589143,
-0.057271194,
-0.0008211237,
0.014837719,
-0.013691228,
0.029142186,
0.06617649,
-0.008498693,
-0.11166283,
-0.0061957138,
-0... | [
-0.11059633,
-0.08116085,
-0.046046253,
-0.001254807,
-0.050658878,
0.00023517216,
-0.0035461213,
0.04823258,
-0.09849152,
-0.032368354,
0.0070589143,
-0.057271194,
-0.0008211237,
0.014837719,
-0.013691228,
0.029142186,
0.06617649,
-0.008498693,
-0.11166283,
-0.0061957138,
-0... |
Characterization of the t(17;19) translocation by gene-specific fluorescent in situ hybridization-based cytogenetics and detection of the E2A-HLF fusion transcript and protein in patients' cells. | This is the first report to comprehensively characterize the E2A-HLF fusion generated from the t(17;19)(q22;p13) translocation in childhood B-lineage acute lymphoblastic leukemia. E2A gene rearrangement and E2A-HLF transcript and protein expression were determined using conventional cytogenetics; fluorescent in situ hy... | 16531271 | [
-0.10199227,
0.013984096,
-0.025949595,
-0.03822054,
-0.020810142,
0.0053386576,
-0.03638787,
0.022204567,
-0.06007982,
-0.010152746,
0.053838108,
-0.04982747,
-0.054449,
-0.06698555,
-0.023041222,
0.00025024958,
-0.05519269,
0.019296193,
-0.07915025,
-0.031288255,
-0.0096414... | [
-0.10199227,
0.013984096,
-0.025949595,
-0.03822054,
-0.020810142,
0.0053386576,
-0.03638787,
0.022204567,
-0.06007982,
-0.010152746,
0.053838108,
-0.04982747,
-0.054449,
-0.06698555,
-0.023041222,
0.00025024958,
-0.05519269,
0.019296193,
-0.07915025,
-0.031288255,
-0.0096414... |
Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. | We report on a series of 24 patients with newly diagnosed mantle cell lymphoma treated with four to six courses of DHAP-rituximab followed by autologous stem cell transplantation for patients <65 years. Three-year overall survival (OS) and event free survival (EFS) rates were 69% and 65% respectively; for the 24 patien... | 16531272 | [
-0.06271381,
-0.0069940807,
-0.03407202,
-0.021641057,
0.0035536052,
0.007479873,
-0.028774885,
0.01184535,
-0.05627207,
-0.03255475,
0.054621708,
-0.04144542,
0.0014415726,
-0.024289623,
-0.0052671884,
0.060477834,
-0.043974202,
0.0071072103,
-0.025154734,
0.0150928395,
-0.0... | [
-0.06271381,
-0.0069940807,
-0.03407202,
-0.021641057,
0.0035536052,
0.007479873,
-0.028774885,
0.01184535,
-0.05627207,
-0.03255475,
0.054621708,
-0.04144542,
0.0014415726,
-0.024289623,
-0.0052671884,
0.060477834,
-0.043974202,
0.0071072103,
-0.025154734,
0.0150928395,
-0.0... |
The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. | The exact rate of lymphomatous meningitis in primary central nervous system lymphomas (PCNSL) is uncertain. In this prospective multicenter study; cerebrospinal fluid (CSF) from 116 immunocompetent patients with newly diagnosed PCNSL was evaluated. Lymphoma cells were found in 18.1%; protein elevation (>45 mg/dL) in 65... | 16531273 | [
-0.014239334,
-0.03661162,
-0.036051646,
-0.041224737,
-0.0037298254,
0.044877898,
0.055784058,
0.056210704,
-0.0008649595,
-0.023892215,
0.022865597,
-0.020305716,
0.014226001,
-0.01289273,
-0.08794255,
-0.012679406,
-0.01841247,
0.038798183,
-0.035198353,
0.0263721,
-0.0634... | [
-0.014239334,
-0.03661162,
-0.036051646,
-0.041224737,
-0.0037298254,
0.044877898,
0.055784058,
0.056210704,
-0.0008649595,
-0.023892215,
0.022865597,
-0.020305716,
0.014226001,
-0.01289273,
-0.08794255,
-0.012679406,
-0.01841247,
0.038798183,
-0.035198353,
0.0263721,
-0.0634... |
The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. | sitivity 86% vs. 62% [p=0.18]). | 16531273 | [
-0.045345847,
0.012551319,
0.0010514453,
0.008847326,
0.014393412,
0.031190125,
0.025657246,
0.012445679,
0.0047901007,
0.020863844,
-0.0015623124,
-0.038505677,
0.0009969748,
0.017681448,
-0.022250365,
-0.0061634174,
0.025630835,
-0.015661089,
-0.013799188,
0.050337326,
0.04... | [
-0.045345847,
0.012551319,
0.0010514453,
0.008847326,
0.014393412,
0.031190125,
0.025657246,
0.012445679,
0.0047901007,
0.020863844,
-0.0015623124,
-0.038505677,
0.0009969748,
0.017681448,
-0.022250365,
-0.0061634174,
0.025630835,
-0.015661089,
-0.013799188,
0.050337326,
0.04... |
BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. | One of the most effective ways to combat different types of cancer is through early diagnosis and administration of effective treatment; followed by efficient monitoring that will allow physicians to detect relapsing disease and treat it at the earliest possible time. Apoptosis; a normal physiological form of cell deat... | 16531274 | [
-0.021058958,
0.021816762,
0.052833524,
0.0057632946,
0.0074982657,
-0.005779913,
0.1129526,
0.031189594,
-0.039831214,
-0.066367626,
0.017283237,
-0.010948265,
-0.032572255,
0.040549133,
-0.02752023,
0.029168785,
-0.01477052,
0.04706358,
-0.019809248,
0.013893063,
-0.0330508... | [
-0.021058958,
0.021816762,
0.052833524,
0.0057632946,
0.0074982657,
-0.005779913,
0.1129526,
0.031189594,
-0.039831214,
-0.066367626,
0.017283237,
-0.010948265,
-0.032572255,
0.040549133,
-0.02752023,
0.029168785,
-0.01477052,
0.04706358,
-0.019809248,
0.013893063,
-0.0330508... |
BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. | well as in the responses of tumours to therapeutic interventions. Many members of the BCL2 (B-cell CLL/lymphoma 2; Bcl-2) family of apoptosis-related genes have been found to be differentially expressed in various malignancies; and some are useful prognostic cancer biomarkers. We have recently cloned a new member of th... | 16531274 | [
-0.062037766,
-0.02670996,
-0.068461,
-0.023498341,
-0.00013089018,
-0.011882989,
0.084893785,
0.03853942,
0.014800209,
-0.04996743,
0.041456643,
-0.059896685,
-0.012117169,
-0.040412866,
-0.006707599,
0.019082367,
-0.03246411,
0.004549793,
-0.09752615,
-0.0065202545,
-0.0491... | [
-0.062037766,
-0.02670996,
-0.068461,
-0.023498341,
-0.00013089018,
-0.011882989,
0.084893785,
0.03853942,
0.014800209,
-0.04996743,
0.041456643,
-0.059896685,
-0.012117169,
-0.040412866,
-0.006707599,
0.019082367,
-0.03246411,
0.004549793,
-0.09752615,
-0.0065202545,
-0.0491... |
BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. | lts have made it clear that a number of coordinating alterations in the BCL2 family of genes must occur to inhibit apoptosis and provoke carcinogenesis in a wide variety of cancers. However; more research is required to increase our understanding of the extent to which and the mechanisms by which they are involved in c... | 16531274 | [
-0.04945072,
-0.021612985,
-0.032940432,
0.0029904863,
0.01415931,
0.0075405003,
0.02473872,
0.020063475,
0.0015177845,
-0.0315245,
0.06812498,
-0.036493618,
0.011968624,
0.0032810194,
-0.015441663,
0.009517461,
-0.053190917,
0.022414455,
-0.089016646,
-0.022441171,
-0.058240... | [
-0.04945072,
-0.021612985,
-0.032940432,
0.0029904863,
0.01415931,
0.0075405003,
0.02473872,
0.020063475,
0.0015177845,
-0.0315245,
0.06812498,
-0.036493618,
0.011968624,
0.0032810194,
-0.015441663,
0.009517461,
-0.053190917,
0.022414455,
-0.089016646,
-0.022441171,
-0.058240... |
BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. | cribe current knowledge of the function and molecular characteristics of a series of classic but also newly discovered genes of the BCL2 family as well as their implications in cancer development; prognosis and treatment. | 16531274 | [
-0.059459813,
0.0009431488,
-0.021176923,
-0.02951774,
0.015554496,
0.027820403,
0.052935675,
0.044369433,
-0.032965455,
-0.06062673,
0.033257183,
-0.050840527,
-0.014321275,
-0.031692453,
-0.012033849,
0.019956963,
-0.0313742,
-0.000927402,
-0.009481215,
0.036254045,
-0.0263... | [
-0.059459813,
0.0009431488,
-0.021176923,
-0.02951774,
0.015554496,
0.027820403,
0.052935675,
0.044369433,
-0.032965455,
-0.06062673,
0.033257183,
-0.050840527,
-0.014321275,
-0.031692453,
-0.012033849,
0.019956963,
-0.0313742,
-0.000927402,
-0.009481215,
0.036254045,
-0.0263... |
The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. | Hepatitis B virus (HBV) infection is the major cause of hepatocellular carcinoma (HCC) worldwide. The pathogenesis of HBV-associated HCC has been studied extensively; and molecular changes during malignant transformation have been identified. It has been proposed that the insertion of HBV DNA into the human genome resu... | 16531275 | [
-0.0012762414,
-0.016662179,
-0.025260719,
0.01334579,
0.023535661,
-0.023669388,
0.050200496,
0.050173752,
0.0016690595,
0.003496918,
0.021302449,
-0.06932322,
-0.025126994,
-0.005114995,
-0.06071131,
-0.0009912392,
-0.0059474353,
-0.012730653,
-0.06359978,
0.027574169,
-0.0... | [
-0.0012762414,
-0.016662179,
-0.025260719,
0.01334579,
0.023535661,
-0.023669388,
0.050200496,
0.050173752,
0.0016690595,
0.003496918,
0.021302449,
-0.06932322,
-0.025126994,
-0.005114995,
-0.06071131,
-0.0009912392,
-0.0059474353,
-0.012730653,
-0.06359978,
0.027574169,
-0.0... |
The molecular diagnosis of hepatitis B virus-associated hepatocellular carcinoma. | s are also involved in the progression of hepatocellular carcinogenesis. Traditional clinical examinations of HCC; such as biopsy; computer tomography; ultrasonic imaging; and detection of such biomarkers as a-fetoprotein; are currently the "gold standard" in diagnosis. These tests diagnose HCC only in the late stages ... | 16531275 | [
0.007339043,
0.027173756,
0.03196443,
0.00067535165,
0.051127113,
-0.0068732835,
0.062278733,
0.040481176,
0.003496525,
-0.04790672,
0.07500063,
-0.02781251,
-0.047347806,
0.053815212,
-0.080376826,
0.026907606,
0.04098686,
-0.003499852,
0.0036928095,
0.04830594,
-0.04061425,... | [
0.007339043,
0.027173756,
0.03196443,
0.00067535165,
0.051127113,
-0.0068732835,
0.062278733,
0.040481176,
0.003496525,
-0.04790672,
0.07500063,
-0.02781251,
-0.047347806,
0.053815212,
-0.080376826,
0.026907606,
0.04098686,
-0.003499852,
0.0036928095,
0.04830594,
-0.04061425,... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.